Literature DB >> 25688295

Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.

Douglas L Nguyen1, Timothy R Morgan1.   

Abstract

Entities:  

Year:  2012        PMID： 25688295      PMCID： PMC4327830          DOI： 10.1002/cld.33

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  29 in total

1.  Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy.

Authors:  E A Jones
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

2.  A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Authors:  Lesley M Arnold; Amy Rosen; Yili Lu Pritchett; Deborah N D'Souza; David J Goldstein; Smriti Iyengar; Joachim F Wernicke
Journal:  Pain       Date:  2005-11-17       Impact factor: 6.961

3.  Treatment of intractable pruritus ani.

Authors:  E B Eusebio; J Graham; N Mody
Journal:  Dis Colon Rectum       Date:  1990-09       Impact factor: 4.585

4.  Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.

Authors:  Astrid Knott; Eric Dieperink; Mark L Willenbring; Sara Heit; Janet M Durfee; Mary Wingert; James R Johnson; Paul Thuras; Samuel B Ho
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

5.  Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Authors:  Robert Roomer; Bettina E Hansen; Harry L A Janssen; Robert J de Knegt
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

6.  A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.

Authors:  Andrew J Holman; Robin R Myers
Journal:  Arthritis Rheum       Date:  2005-08

7.  Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.

Authors:  M R Kraus; A Schäfer; K Schöttker; C Keicher; B Weissbrich; I Hofbauer; M Scheurlen
Journal:  Gut       Date:  2007-12-13       Impact factor: 23.059

8.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

9.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

10.  Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

Authors:  Alejandro Soza; James E Everhart; Marc G Ghany; Edward Doo; Theo Heller; Kittichai Promrat; Yoon Park; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425
View more
  3 in total

1.  Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.

Authors:  Vinod K Dixit; Jayanta K Ghosh; Sangey C Lamtha; Pankaj Kaushik; Sundeep K Goyal; Manas K Behera; Neha Singh; Ashok K Jain
Journal:  J Clin Exp Hepatol       Date:  2014-06-18

2.  Viral Hepatitis in South Korea.

Authors:  Stella C Pak; Yaseen Alastal; Zubair Khan; Umar Darr
Journal:  Euroasian J Hepatogastroenterol       Date:  2017-09-29

3.  In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.

Authors:  Phaedra Eleftheriou; Dionysia Amanatidou; Anthi Petrou; Athina Geronikaki
Journal:  Molecules       Date:  2020-05-29       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.